105 related articles for article (PubMed ID: 17183156)
1. Plasma amyloid-beta, Abeta1-42, load is reduced by haemodialysis.
Rubio I; Caramelo C; Gil A; López MD; de Yébenes JG
J Alzheimers Dis; 2006 Dec; 10(4):439-43. PubMed ID: 17183156
[TBL] [Abstract][Full Text] [Related]
2. A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease.
Kitaguchi N; Hasegawa M; Ito S; Kawaguchi K; Hiki Y; Nakai S; Suzuki N; Shimano Y; Ishida O; Kushimoto H; Kato M; Koide S; Kanayama K; Kato T; Ito K; Takahashi H; Mutoh T; Sugiyama S; Yuzawa Y
J Neural Transm (Vienna); 2015 Nov; 122(11):1593-607. PubMed ID: 26228626
[TBL] [Abstract][Full Text] [Related]
3. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.
Chouraki V; Beiser A; Younkin L; Preis SR; Weinstein G; Hansson O; Skoog I; Lambert JC; Au R; Launer L; Wolf PA; Younkin S; Seshadri S
Alzheimers Dement; 2015 Mar; 11(3):249-57.e1. PubMed ID: 25217292
[TBL] [Abstract][Full Text] [Related]
4. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease.
Chiu MJ; Yang SY; Chen TF; Chieh JJ; Huang TZ; Yip PK; Yang HC; Cheng TW; Chen YF; Hua MS; Horng HE
Curr Alzheimer Res; 2012 Dec; 9(10):1142-8. PubMed ID: 22950866
[TBL] [Abstract][Full Text] [Related]
5. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.
Pannee J; Törnqvist U; Westerlund A; Ingelsson M; Lannfelt L; Brinkmalm G; Persson R; Gobom J; Svensson J; Johansson P; Zetterberg H; Blennow K; Portelius E
Neurosci Lett; 2014 Jun; 573():7-12. PubMed ID: 24796810
[TBL] [Abstract][Full Text] [Related]
6. Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.
Coppus AM; Schuur M; Vergeer J; Janssens AC; Oostra BA; Verbeek MM; van Duijn CM
Neurobiol Aging; 2012 Sep; 33(9):1988-94. PubMed ID: 21958962
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.
Rembach A; Faux NG; Watt AD; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Roberts BR; Perez KA; Li QX; Laws SM; Taddei K; Rainey-Smith S; Robertson JS; Vandijck M; Vanderstichele H; Barnham KJ; Ellis KA; Szoeke C; Macaulay L; Rowe CC; Villemagne VL; Ames D; Martins RN; Bush AI; Masters CL;
Alzheimers Dement; 2014 Jan; 10(1):53-61. PubMed ID: 23491263
[TBL] [Abstract][Full Text] [Related]
8. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.
Le Bastard N; Leurs J; Blomme W; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2010; 21(1):291-301. PubMed ID: 20421698
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.
Hansson O; Stomrud E; Vanmechelen E; Östling S; Gustafson DR; Zetterberg H; Blennow K; Skoog I
J Alzheimers Dis; 2012; 28(1):231-8. PubMed ID: 21955816
[TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.
Poljak A; Crawford JD; Smythe GA; Brodaty H; Slavin MJ; Kochan NA; Trollor JN; Wen W; Mather KA; Assareh AA; Ng PC; Sachdev PS
Curr Alzheimer Res; 2016; 13(3):243-55. PubMed ID: 26679856
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.
Hsu JL; Lee WJ; Liao YC; Wang SJ; Fuh JL
Alzheimers Res Ther; 2017 Nov; 9(1):91. PubMed ID: 29169407
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model.
Jin WS; Shen LL; Bu XL; Zhang WW; Chen SH; Huang ZL; Xiong JX; Gao CY; Dong Z; He YN; Hu ZA; Zhou HD; Song W; Zhou XF; Wang YZ; Wang YJ
Acta Neuropathol; 2017 Aug; 134(2):207-220. PubMed ID: 28477083
[TBL] [Abstract][Full Text] [Related]
13. Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.
Kitaguchi N; Kawaguchi K; Nakai S; Murakami K; Ito S; Hoshino H; Hori H; Ohashi A; Shimano Y; Suzuki N; Yuzawa Y; Mutoh T; Sugiyama S
Blood Purif; 2011; 32(1):57-62. PubMed ID: 21346337
[TBL] [Abstract][Full Text] [Related]
14. Changes in copper and zinc in chronic haemodialysis patients.
Hosokawa S; Nishitani H; Imai T; Nishio T; Tomoyoshi T; Sawanishi K
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():247-50. PubMed ID: 3991505
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
[TBL] [Abstract][Full Text] [Related]
16. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).
Sparks DL; Petanceska S; Sabbagh M; Connor D; Soares H; Adler C; Lopez J; Ziolkowski C; Lochhead J; Browne P
Curr Alzheimer Res; 2005 Dec; 2(5):527-39. PubMed ID: 16375656
[TBL] [Abstract][Full Text] [Related]
18. Association of plasma β-amyloid with MRI markers of structural brain aging the 3-City Dijon study.
Kaffashian S; Tzourio C; Soumaré A; Dufouil C; Mazoyer B; Schraen-Maschke S; Buée L; Debette S
Neurobiol Aging; 2015 Oct; 36(10):2663-70. PubMed ID: 26242707
[TBL] [Abstract][Full Text] [Related]
19. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
20. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
